GMAB · NASDAQ · STOCK
Genmab A/S (GMAB) Stock Analysis
$37.05
52W $23.62 – $40.17
56/100
$22.76B
28.6
0.65
Is GMAB Bullish or Bearish?
Mixed.
Innellis AI committee rates Genmab A/S (GMAB) Watch with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.21 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.79 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 26.8 is moderate-to-rich — Value
- EPS declining -36.4% YoY despite any revenue growth — Growth
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 61%
of 192 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 26.8 is moderate-to-rich
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -36.4% YoY despite any revenue growth
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Weekly RSI at 80 -- overbought on the larger timeframe too
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 15.1% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.8 to 55.8.
- New bearish signals: 3 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
60.1
Neutral
MACD Histogram
0.071
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.82
Inside Bands
Price vs Moving Averages
EMA 9
$36.34
Above
EMA 21
$35.43
Above
EMA 50
$33.61
Above
EMA 200
$29.98
Above
Fundamental Analysis
Valuation
70
Growth
70
Profitability
62
Financial Health
90
Cash Flow
70
Valuation
P/E Ratio
28.6×
P/B Ratio
3.77×
PEG Ratio
-0.33
Dividend Yield
0.00%
52W High
$40.17
52W Low
$23.62
Quality & Growth
ROE
1652.1%
ROA
750.4%
Gross Margin
3991.8%
Operating Margin
1381.2%
Revenue Growth YoY
—
Debt / Equity
0.89
AI Fundamental Assessment
P/E ratio of 28.6 (moderate relative to a 15-40x range); Price-to-book of 3.8x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 16.5%; Return on assets of 7.5%; Net margin of 8.2%; Gross margin of 39.9%; Current ratio of 2.46 (healthy short-term liquidity); Debt-to-equity of 0.89; Free cash flow per share is positive (1.42); Most recent quarter beat estimates by 36.6%; EPS growth accelerating (-61.0% -> +491.6% QoQ); Analyst estimates rising over recent quarters
Get the Full GMAB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →